Recombinant Human Endoglin (ENG)

What is the molecular structure of human endoglin?

Human endoglin is a homodimeric type I membrane glycoprotein consisting of an extracellular domain (561 amino acids), a hydrophobic transmembrane domain, and a short cytoplasmic tail. The extracellular region comprises approximately 90% of the protein and contains N-linked glycosylation sites and cysteine residues involved in interchain disulfide bonding that maintain its dimeric structure. The protein undergoes post-translational modifications including glycosylation and phosphorylation, which are critical for its proper folding and function . Recombinant endoglin produced in bacterial systems often results in inclusion bodies due to lack of these modifications, making mammalian expression systems preferable for functional studies .

What is the difference between membrane-bound endoglin and soluble endoglin?

Membrane-bound endoglin functions as a co-receptor for TGF-β/BMP signaling on cell surfaces, particularly in endothelial cells. Soluble endoglin (sEng) is generated through proteolytic cleavage of the extracellular domain by matrix metalloproteinases (MMP-14 or MMP-12) at the juxtamembrane region . While membrane endoglin promotes TGF-β signaling, sEng acts as an antagonist, limiting TGF-β1 signaling and type I collagen synthesis . This antagonistic function makes sEng potentially therapeutic in conditions characterized by excessive fibrosis .

What are the main signaling pathways associated with endoglin?

Endoglin primarily modulates TGF-β family signaling through interaction with type I and type II TGF-β receptors. It particularly influences canonical Smad-dependent pathways, with endoglin being required for TGF-β1 signaling in human cardiac fibroblasts . Research indicates that endoglin selectively affects certain branches of TGF-β signaling, particularly those involved in fibrosis and tissue remodeling. Endoglin has also been shown to bind directly to BMP9 and BMP10, as demonstrated by functional binding assays with recombinant endoglin-GFP fusion proteins .

What expression systems are most effective for producing functional recombinant human endoglin?

Mammalian expression systems are optimal for producing functional recombinant human endoglin due to the protein's requirement for post-translational modifications. CHO-K1 cells have been successfully used to express soluble forms of endoglin fused with enhanced green fluorescent protein (EGFP) . The procedure involves:

• Cloning the extracellular domain of endoglin (Glu26–Gly586) into an expression vector such as pEGFP-N1

• Including the native signal peptide at the N-terminus for proper secretion

• Adding a detection/purification tag if needed (e.g., Strep-tag II)

• Transfecting mammalian cells and selecting stable cell lines

• Harvesting secreted protein from culture supernatants

Bacterial expression systems typically result in inclusion bodies and improperly folded proteins due to the lack of glycosylation machinery .

What methods are recommended for purification and validation of recombinant endoglin?

Purification and validation of recombinant endoglin should employ multiple complementary techniques:

Purification:

• Affinity chromatography using anti-endoglin antibodies or engineered tags (His-tag, Strep-tag)

• Size exclusion chromatography to separate dimeric from monomeric forms

Validation:

• SDS-PAGE under reducing and non-reducing conditions to confirm dimeric structure (~275 kDa under non-reducing conditions)

• Western blot using both anti-endoglin and anti-tag antibodies

• ELISA for quantification (achieving concentrations of 5-20 ng/mL in standard culture systems)

• Functional binding assays with known ligands (BMP9, BMP10)

• Fluorescence detection if using GFP-fusion constructs

How can researchers generate fluorescently labeled endoglin for imaging studies?

Researchers can generate fluorescently labeled endoglin by creating fusion proteins with fluorescent proteins. A validated approach involves:

• Cloning the extracellular domain of endoglin (aa Glu26-Gly586) preceded by its native signal peptide

• Inserting this sequence into the pEGFP-N1 vector in-frame with EGFP

• Introducing a flexible linker sequence (approximately 19 amino acids) between endoglin and EGFP

• Transfecting mammalian cells and selecting stable transfectants

• Confirming expression through fluorescence microscopy and flow cytometry

This approach yields a dimeric protein of approximately 844 amino acids per monomer that retains both fluorescent properties and biological activity . The fluorescent fusion protein enables tracking of endoglin binding to cell surface receptors and identification of novel interactors through direct visualization or FRET analysis .

How can recombinant endoglin be used to study TGF-β signaling pathways?

Recombinant endoglin can serve as a powerful tool for dissecting TGF-β signaling pathways through several approaches:

• Loss-of-function studies: Using neutralizing antibodies or siRNA to reduce endoglin expression in cellular models, followed by assessment of TGF-β pathway activation through phospho-Smad analysis

• Gain-of-function studies: Overexpressing full-length endoglin (AdFL-Eng) in target cells to amplify TGF-β responses

• Pathway inhibition studies: Using soluble endoglin to selectively inhibit certain branches of TGF-β signaling, particularly those involved in fibrosis

• Binding competition assays: Using recombinant endoglin to identify binding partners and characterize binding kinetics with BMP and TGF-β family members

• Reporter assays: Employing reporter cell lines like C2C12-BRE to assess the impact of endoglin on BMP9/BMP10 signaling

These approaches allow researchers to delineate the specific contribution of endoglin to various branches of TGF-β family signaling.

What models are recommended for studying endoglin's role in cardiovascular disease?

Several validated models can be used to study endoglin's role in cardiovascular disease:

In vitro models:

• Human cardiac fibroblasts (hCF) for studying TGF-β1-induced collagen synthesis and fibrosis

• Endothelial cell cultures for angiogenesis and vascular remodeling studies

• Co-culture systems combining cardiomyocytes and fibroblasts

In vivo models:

• Pressure overload-induced heart failure in mice through transverse aortic constriction (TAC)

• Adenoviral delivery of soluble endoglin (AdhsEng) to modulate endoglin activity in vivo

• Endoglin heterozygous (Eng+/-) mice as a model of haploinsufficiency

Research has shown that reduced endoglin expression attenuates cardiac fibrosis, preserves left ventricular function, and improves survival in pressure-overload induced heart failure models . This suggests targeting endoglin may offer a novel approach to managing heart failure.

How does soluble endoglin affect cardiac fibrosis in experimental models?

Soluble endoglin has been shown to significantly attenuate cardiac fibrosis in experimental models through several mechanisms:

• Inhibition of TGF-β1 signaling: sEng limits TGF-β1-induced Smad2/3 phosphorylation in cardiac fibroblasts

• Reduction of collagen synthesis: Treatment with sEng decreases type I collagen production in TGF-β1-stimulated cardiac fibroblasts

• Improved cardiac function: In pressure overload-induced heart failure models, adenoviral delivery of human sEng preserves left ventricular function

• Enhanced survival: Mice treated with AdhsEng prior to transverse aortic constriction show improved survival compared to controls

• Selective modulation: Unlike complete TGF-β blockade, sEng selectively inhibits specific aspects of TGF-β signaling, potentially offering a more targeted therapeutic approach

These findings suggest that soluble endoglin functions as an autocrine antagonist of TGF-β1 signaling in heart failure, identifying it as a potential therapeutic approach to limit cardiac fibrosis.

How can apparent contradictions between membrane-bound and soluble endoglin functions be reconciled in experimental design?

The seemingly contradictory functions of membrane-bound and soluble endoglin require careful experimental design:

• Clear distinction in models: Experiments should clearly distinguish between manipulating membrane-bound endoglin (through siRNA, CRISPR, or overexpression) versus soluble endoglin (through recombinant protein addition or adenoviral expression)

• Temporal considerations: Account for acute versus chronic effects, as short-term and long-term modulation of endoglin may yield different outcomes

• Context-dependent effects: Recognize that endoglin's effects may vary by cell type, with different outcomes in endothelial cells versus fibroblasts

• Mechanistic focus: Include readouts that measure both canonical (Smad-dependent) and non-canonical TGF-β pathways to capture differential modulation

• Concentration effects: Titrate both membrane-bound and soluble endoglin levels, as concentration-dependent effects have been observed

Understanding these considerations helps reconcile apparent contradictions, recognizing that membrane endoglin promotes TGF-β signaling while soluble endoglin acts as a decoy receptor, inhibiting certain aspects of TGF-β signaling.

What are the limitations of current techniques for studying endoglin function?

Current techniques for studying endoglin function have several limitations researchers should consider:

• Antibody specificity issues: Many commercial antibodies show cross-reactivity between different species or recognize epitopes affected by glycosylation

• Transient expression challenges: Full-length endoglin expression can be toxic to some cell types, making stable expression difficult

• Protein stability concerns: Recombinant soluble endoglin may have limited stability in certain experimental conditions

• Physiological relevance: Concentrations of recombinant endoglin used in vitro often exceed physiological levels (typical yields of 5-20 ng/mL in culture systems)

• Model limitations: Animal models may not fully recapitulate human endoglin biology due to species-specific differences in expression patterns and binding affinities

• Complex signaling networks: Endoglin interacts with multiple signaling pathways, making it difficult to isolate its specific effects

Researchers can address these limitations through careful controls, validation with multiple techniques, and using physiologically relevant concentrations wherever possible.

What novel approaches are emerging for targeting endoglin in disease models?

Several innovative approaches for targeting endoglin are emerging in disease research:

• Gene therapy approaches: Adenoviral delivery of soluble endoglin has shown promise in cardiovascular disease models

• Engineered fusion proteins: Creating endoglin-based fusion proteins with enhanced stability or targeting capabilities, such as the endoglin-GFP fusion protein

• Selective antibodies: Developing antibodies that specifically target either membrane-bound or soluble endoglin forms

• Small molecule modulators: Identifying compounds that selectively modulate endoglin expression or shedding

• Peptide inhibitors: Designing peptides that disrupt specific endoglin-ligand interactions while preserving others

• MMP modulation: Targeting the matrix metalloproteinases (MMP-14, MMP-12) that generate soluble endoglin to control its levels in vivo

These approaches offer potential for more selective modulation of endoglin function in disease states, particularly in cardiovascular conditions where complete TGF-β blockade has shown mixed results.

What are common challenges in expressing recombinant endoglin and how can they be addressed?

Researchers frequently encounter these challenges when expressing recombinant endoglin:

Challenge 1: Poor expression levels

• Solution: Optimize codon usage for the host cell system

• Solution: Include the native signal peptide (Met1-Glu25) for proper secretion

• Solution: Consider using strong promoters like CMV for mammalian expression

Challenge 2: Protein aggregation/inclusion bodies

• Solution: Express in mammalian cells rather than bacterial systems

• Solution: Ensure proper glycosylation by using CHO-K1 or HEK293 cells

• Solution: Include the appropriate disulfide bond-forming environment

Challenge 3: Improper folding

• Solution: Include proper linker sequences between fusion domains

• Solution: Verify dimeric structure by non-reducing SDS-PAGE

• Solution: Confirm activity through functional binding assays with BMP9/10

Challenge 4: Low secretion efficiency

• Solution: Verify signal peptide functionality

• Solution: Consider optimizing culture conditions (reduced serum, lower temperature)

• Solution: Harvest at optimal timepoints (typically 48-72 hours post-transfection)

How can researchers confirm the biological activity of recombinant endoglin preparations?

Biological activity of recombinant endoglin can be confirmed through multiple complementary assays:

• Ligand binding assays: Verify binding to known ligands such as BMP9 and BMP10 using ELISA or surface plasmon resonance

• Functional inhibition: Test the ability of soluble endoglin to neutralize BMP9 and BMP10 signaling in reporter cell lines such as C2C12-BRE

• Signaling modulation: Assess the impact on TGF-β-induced Smad phosphorylation in target cells using Western blotting for phospho-Smads

• Collagen synthesis: Measure the effect on type I collagen production in cardiac fibroblasts or other relevant cell types

• Cellular phenotype: Evaluate impacts on cellular processes like migration, proliferation, or differentiation depending on the cell type being studied

A recombinant endoglin preparation showing concentration-dependent activity in at least two of these assays can be considered biologically active.

What strategies can optimize the yield and purity of recombinant endoglin?

Several strategies can optimize yield and purity of recombinant endoglin:

Yield optimization:

• Use serum-free media formulations specifically designed for protein production

• Consider biphasic culture processes (growth phase followed by production phase)

• Optimize cell density and harvest timing

• Evaluate different mammalian expression systems (CHO-K1, HEK293, ExpiCHO)

Purification strategies:

• Implement a multi-step purification process including:

  • Initial clarification by centrifugation and filtration

  • Affinity chromatography using anti-endoglin antibodies or engineered tags

  • Size exclusion chromatography to separate dimeric from monomeric forms

  • Ion exchange chromatography for final polishing

Quality control:

• Verify protein integrity by mass spectrometry

• Confirm glycosylation pattern by lectin binding assays

• Assess endotoxin levels for in vivo applications

• Analyze batch-to-batch consistency using standardized functional assays

Careful optimization of these parameters can improve yields from the typical 5-20 ng/mL range reported in standard culture systems .